Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. - Wikidata - wikimedia - TriplyDB

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

http://www.wikidata.org/entity/Q40664845

about

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Amyloid-β Receptors: The Good, the Bad, and the Prion Protein Alzheimer's Disease: Mechanism and Approach to Cell Therapy Drug development in Alzheimer's disease: the path to 2025 Expanding the phenotypic associations of globular glial tau subtypes.Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges Immune Regulation of Antibody Access to Neuronal Tissues Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.Differential diagnosis of neurodegenerative diseases using structural MRI data The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment.Function and clinical meaningfulness of treatments for mild Alzheimer's disease.A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.Assessing quality of life in Alzheimer's disease: Implications for clinical trials.Amyloid-beta immunotherapy: the hope for Alzheimer disease?New drugs in psychiatry: focus on new pharmacological targets.Dementia: What pharmacists need to know.Developing therapeutic vaccines against Alzheimer's disease.Alzheimer Disease: Scientific Breakthroughs and Translational Challenges.Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.Stem Cell Therapy for Alzheimer's Disease: A Review of Recent Clinical Trials.The road to restoring neural circuits for the treatment of Alzheimer's disease.Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

P2860

Q26745928-62D58AE2-F418-40C3-BD97-1CD26D3920D5 Q26771532-E8FD486A-7F1B-46FD-8BD1-29883173F495 Q26778149-79C0102D-94C2-4431-912E-3FE86B1219F8 Q27007748-D42C263F-D0A0-43CB-8A98-D531A3BF253B Q27315448-E2707E5B-8079-401B-816F-17769E8A3460 Q28072061-63554F25-AF88-45FB-9E08-0A08077F76CE Q28733365-18BFBC57-4137-4271-B468-CA6A65C95B2E Q28828354-7C34D39D-2C91-4429-96A2-99B59506472F Q30835636-3BF793FC-2A49-40E0-A5AB-68199BD5DC43 Q31082974-6E9A3A83-71D2-400B-8838-D6646B37CB40 Q31147579-53E823AE-C51D-442F-917C-8E3C0C811D31 Q33556068-64D6E231-A2F2-4D86-B614-FB90006CAE5A Q36204262-5D6DCE24-C0E8-49B3-B628-002D79816896 Q36725034-90ACC60D-5FC9-4A79-83FD-81662CB5E522 Q36796489-EB90ED3C-9E01-49D9-AFB9-422D6B233F7D Q36853502-51B56A27-41A7-41CE-BF78-30DE2242FD29 Q36934148-948B7D6D-06C6-4276-8AEB-DE5A892BAE6C Q36964826-CA3CA636-176D-4B4C-9E5B-706A9F28E8A9 Q37054759-1D81FE17-457A-4B34-8496-DCB577239DEC Q37270930-00EEB7FB-6EA7-4B03-9370-C6FBB1B8E481 Q37388872-6C18E4A2-8E6F-4823-A713-5151DC1BE278 Q37473219-B7339167-6EF6-4D45-BC8F-31D770F04FF9 Q37501943-B7507A9E-6570-490F-AF45-B309CCED7397 Q37589619-11BB5579-AE4F-4C3F-944C-C70725E2CF95 Q37645462-4E734419-5BBA-4AC0-9BB8-DC2027FFACEE Q37679265-9BD4774B-6247-4AB8-B2EB-7BF70A2BEA1A Q37730207-A92B184B-A926-4C9A-8527-B1EF04E11D40 Q37741796-A0E07E9F-6420-4D9C-B944-934DFF15D262 Q38636151-4A0A5F2D-0FDC-4379-8964-40E75DC12DBD Q38675107-04D1E63C-11E4-4A47-987F-E1BA98B7165E Q38692086-4015EBD2-D0C7-49CB-8816-3A8AF26BBFFF Q38739937-754108F2-62B6-4560-8305-80801C998570 Q38769710-16FECE72-3548-41EC-8445-F23B925D2233 Q38802634-45BFCE12-F3F1-4D6C-9D04-A68131A318DA Q38806886-0A36D816-3106-4C09-85F5-124170E0D6AF Q38807908-639A4221-1A67-4EFF-828C-BB3267411073 Q38810754-D11B4023-8739-488F-96E7-DF2F2AFA0572 Q38938919-8F970EA9-D581-4943-8DF9-BB61022F6C97 Q39004340-00BF4856-1BF7-4EDE-ACE3-3AF4A2CAF760 Q39016306-047C6FBD-C9A2-4E77-9871-492E5A673AC4

P2860

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

http://www.wikidata.org/entity/Q40664845

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

@en

type

label

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

@en

prefLabel

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

@en

P1433

Q40664845-83470A75-9F11-475D-B84B-0D40B675E514

P1476

Q40664845-79D17E1B-F1D2-42B1-BEF2-E92C48292DA4

P2093

Q40664845-025E4A49-B28C-4B52-B013-73A52ACEB32E

Q40664845-2F0005E5-A440-440E-8942-40E2252E2D0B

Q40664845-3D27D3A8-EB8E-449A-9AB8-3DB5C5A0606A

Q40664845-4A5A8E69-7AD4-4A71-A78F-1C97E55DC827

Q40664845-4B149980-6511-40CD-AA79-DABF7855062A

Q40664845-6353331D-6EBA-49CE-9AD3-DFD0372E9758

Q40664845-6C60D115-9CD3-47D1-A70D-B201F99570D7

Q40664845-93E3EB82-8CE3-454F-B3A3-877D7F017737

Q40664845-D74407B3-B764-443D-ABBC-CCF0DE78F042

Q40664845-E3AED62E-E302-4724-B31F-578CF80B8F46

P304

Q40664845-91E52CCB-60B1-49BF-8E79-A93CFC0D4B86

P31

Q40664845-8490F232-E85F-4AF8-A37E-24162E27B3F2

P356

Q40664845-9DFF2EC4-84F6-4194-9A10-AF644FF495CF

P433

Q40664845-F47500BE-2B25-433B-B6FD-8F2126214A0D

P478

Q40664845-8B93FB14-2D7F-4A98-B0CC-460EBB13D12E

P577

Q40664845-87EB7C9F-D75F-4FBB-A73D-4995A9FEFCED

P5875

Q40664845-1125FFDE-A93D-4E8C-AE3B-58B751857738

P698

Q40664845-ACA3D604-12DD-4637-B593-C506D144AAA6

P921

Q40664845-43D34D13-8216-4EC0-AD02-B91FED703B4D

Q40664845-9B73A982-A946-405C-9FB8-CFD1E5BC30E3

P356

J.JALZ.2015.06.1893

P1433

Alzheimer's and Dementia

P1476

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

@en

P2093

Christopher Carlson

http://www.w3.org/2001/XMLSchema#string

Eric R Siemers

http://www.w3.org/2001/XMLSchema#string

Gopalan Sethuraman

http://www.w3.org/2001/XMLSchema#string

Hong Liu-Seifert

http://www.w3.org/2001/XMLSchema#string

Karen L Sundell

http://www.w3.org/2001/XMLSchema#string

Michael Case

http://www.w3.org/2001/XMLSchema#string

Michael J Pontecorvo

http://www.w3.org/2001/XMLSchema#string

Robert A Dean

http://www.w3.org/2001/XMLSchema#string

Ronald Demattos

http://www.w3.org/2001/XMLSchema#string

Sherie A Dowsett

http://www.w3.org/2001/XMLSchema#string

P304

110-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2015.06.1893

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280694389

http://www.w3.org/2001/XMLSchema#string

P698

26238576

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

phase III clinical trial